Compare Synopsys, Inc. (SNPS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Synopsys, Inc. trades at $477.98 (market cap $94.77B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Synopsys, Inc. is far larger — about 19.4× Travere Therapeutics Inc. Common Stock's market cap, and Synopsys, Inc. is more actively traded (2,520,237 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Synopsys, Inc. for 72 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SNPS | TVTX | |
|---|---|---|
Market Cap | $94.77B | $4.88B |
Volume | 2,520,237 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $534.56 | $67.52 |
52-Week Low | $367.70 | $26.79 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $102.00B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $479.93, down 4.49% today but remains in a strong technical uptrend with bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $3.91 beating expectations by 6.5% and maintains strong profitability with 72.38% gross margins. Recent investor day announcements highlighted transformative AI partnerships with OpenAI and Amazon, driving positive sentiment and analyst upgrades.
Outlook remains positive with 93% analyst buy ratings and $575.93 consensus target offering 20% upside. Key opportunities include AI-driven chip design growth and Ansys integration synergies, while risks involve execution challenges and premium valuation at 86.3 P/E. The stock presents a compelling growth story but requires monitoring of integration progress and competitive pressures.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
